MARKET

BCAB

BCAB

Bioatla, Inc.
NASDAQ
3.440
-0.020
-0.58%
After Hours: 3.390 -0.05 -1.45% 19:33 03/28 EDT
OPEN
3.500
PREV CLOSE
3.460
HIGH
3.550
LOW
3.325
VOLUME
703.77K
TURNOVER
0
52 WEEK HIGH
4.068
52 WEEK LOW
1.240
MARKET CAP
165.45M
P/E (TTM)
-1.3312
1D
5D
1M
3M
1Y
5Y
BioAtla Price Target Maintained With a $12.00/Share by JMP Securities
Dow Jones · 22h ago
JMP Securities Reiterates Market Outperform on BioAtla, Maintains $12 Price Target
Benzinga · 23h ago
BioAtla Price Target Cut to $7.00/Share From $10.00 by HC Wainwright & Co.
Dow Jones · 2d ago
BioAtla Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 2d ago
HC Wainwright & Co. Maintains Buy on BioAtla, Lowers Price Target to $7
Benzinga · 2d ago
Optimistic Outlook for BioAtla’s Pipeline Progression and Potential Partnerships
TipRanks · 2d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 2d ago
BioAtla Q4 EPS $(0.56) Beats $(0.79) Estimate
Benzinga · 2d ago
More
About BCAB
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include BA3011 (Mecbotamab vedotin), BA3021 (Ozuriftabmab vedotin), BA3071 and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL, which is a protein kinase receptor. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications, including renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder and gastric cancer, and cervical cancer. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.

Webull offers Bioatla Inc stock information, including NASDAQ: BCAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCAB stock methods without spending real money on the virtual paper trading platform.